Skip to main content
. 2011 Feb 23;173(7):768–777. doi: 10.1093/aje/kwq423

Figure 4.

Figure 4.

Change in hematocrit (top panel) and erythropoietin (EPO) use (bottom panel), by altitude exposure group, among US patients with hematocrit ≥32% and average EPO use <10,800 units/week before the altitude change, 1992–2004. One foot = 0.3 m.